Year of Publication



Public Health

Degree Name

Master of Public Health (M.P.H.)

Committee Chair

Julia Costich

Committee Member

Kathi Harp

Committee Member

Sarah Cotner



Dalbavancin is an antibiotic within the class of medications known as lipoglycopeptides. This medication is given to patients presenting to the hospital with acute skin and skin-structure infections (ABSSSI). This is a unique medication because it is given as a one-time dose in the outpatient setting and it could prevent patients from requiring admission to the hospital.


The emergency department (ED) at Good Samaritan community hospital performed a trial period with dalbavancin and data was collected from November 2018 to March 2020. Retrospective chart review was performed to obtain patient data and outcomes. Patients would be contacted by a clinical pharmacist within 72 hours of treatment.


Ten patients received dalbavancin in the ED during the trial period. Two patients were reached on follow-up and noted improvement in the initial lesion. Two patients returned to the ED within 30 days, and one of these patients was admitted.


Dalbavancin provides another therapy option to the treatment of ABSSSIs. The one-time dosing is advantageous for outpatient treatment of patients presenting with ABSSSIs. This case series suggests dalbavancin can have positive effects when implemented in community hospital settings.